[1] ZHANG Z H，HUANG Y，WANG X M，et al.Research advance of small molecular targeted anti-tumor agents TKIs[J] . Chin Prescr Drug(中国处方药)，2006，6（51）：50-53. [2] FAIVRE S，DELBALDO C，VERA K，et al. Safety，pharmacokinetic，and antitumor activity of SU11248，a novel oral multitarget tyrosine kinase inhibitor，in patients with cancer[J] . J Clin Oncol，2006，24(1)：25-35. [3] MOTZER R J，MICHAELSON M D，REDMAN B G，et al. Activity of SU11248，a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor，in patients with metastatic renal cell carcinoma[J] . J Clin Oncol，2006，24(1)：16-24. [4] MOTZER R J，RINI B I，BUKOWSKI R M，et al. Sunitinib in patients with metastatic renal cell carcinoma[J] . Jama，2006，295(21)：2516-2524. [5] DEMETRI G D，VAN OOSTEROM A T，GARRETT C R，et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib： a randomised controlled trial[J] . Lancet，2006，368(9544)：1329-1338. [6] HAHN O，STADLER W. Sorafenib[J] . Curr Opin Oncol，2006，18(6)：615-621. [7] JAIN L，VENITZ J，FIGG W D. Randomized discontinuation trial of Sorafenib (BAY 43-9006) [J] . Cancer Biol Ther，2006，5(10)：1270-1272. [8] GORE M E，ESCUDIER B. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma[J] . Oncology (Williston Park)，2006，20(6 Suppl 5)：19-24. [9] ABOU-ALFA G K，SCHWARTZ L，RICCI S，et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma[J] . J Clin Oncol，2006，24(26)：4293-4300. [10] EISEN T，AHMAD T，FLAHERTY K T，et al. Sorafenib in advanced melanoma： a phase Ⅱ randomised discontinuation trial analysis[J] . Br J Cancer，2006，95(5)：581-586. [11] HEYMACH J V. ZD6474-clinical experience to date[J] . Br J Cancer，2005，92(Suppl 1)：14-20. [12] LEE D. Pphase Ⅱ data with ZD6474，a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor，in previously treated advanced non-small-cee lung cancer[J] . Clin Lung Cancer，2005，7(2)：89-91. [13] RYAN A J ，WEDGE S R. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity[J] . Br J Cancer，2005，92(Suppl 1)：6-13. [14] LI Y. The multitargeted anti-tumor new angent： ZD6474[J] . Oncol Prog（癌症进展），2006，4(3)：206-210. [15] MILLER K D，TRIGO J M，WHEELER C，et al. A multicenter phase Ⅱ trial of ZD6474，a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor，in patientswith previously treated metastatic breast cancer[J] . Clin Cancer Res，2005，11(9)：3369-3376. [16] TALPAZ M，SHAH N P，KANTARJIAN H，et al. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias[J] . New Eng J Med，2006，354(24)：2531-2541. [17] ROBOZ G J，GILES F J，LIST A F，et al. Phase 1 study of PTK787/ZK 222584，a small molecule tyrosine kinase receptor inhibitor，for the treatment of acute myeloid leukemia and myelodysplastic syndrome[J] . Leukemia，2006，20(6)：952-957. [18] TYAGI P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer： preliminary results from the CONFIRM-1 trial[J] . Clin Colorectal Cancer，2005，5(1)：24-26. [19] ZHONG Y，LI Z Y，YOU Q D. Investigations in vascular endothelial growth factor receptor family tyrosine kinase inhibitor[J] . Chin New Drugs J(中国新药杂志)，2006，15(3)：181-185. [20] ZHOU H，KIM Y S，PELETIER A，et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation，radiosensitization，and resistance[J] . Int J Radiat Oncol Biol Phys，2004，58(2)：344-352. [21] BENCE A K，ANDERSON E B，HALEPOTA M A，et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016，a dual EGFR-ErbB2 inhibitor，in healthy subjects[J] . Invest New Drugs，2005，23(1)：39-49. [22] PATYNA S，LAIRD A D，MENDEL D B，et al. SU14813： a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity[J] . Mol Cancer Ther，2006，5(7)：1774-1782. [23] ALBERT D H，TAPANG P，MAGOC T J，et al. Preclinical activity of ABT-869，a multitargeted receptor tyrosine kinase inhibitor[J] . Mol Cancer Ther，2006，5(4)：995-1006. [24] KUENEN B C，GIACCONE G，RUIJTER R，et al. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies[J] . Clin Cancer Res，2005，11(17)：6240-6246. [25] WANG J，SHI Y K. Research developments for gastrointestinal stromal tumors [J] . Chin Prescr Drug(中国处方药)，2006，8(53)：34-37.